The FDA has cleared an investigational new drug application and granted Fast Track designation to ACDN-01, the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease.
Ascidian Therapeutics has announced that the FDA has cleared its investigational new drug (IND) application and granted Fast Track designation for ACDN-01. According to a company press release, ACDN-01 is the only clinical stage therapeutic targeting the genetic cause of Stargardt disease and the first-ever clinical stage RNA exon editor.1
According to the Foundation Fighting Blindness, Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. The inherited disease is often diagnosed in childhood or adolescence. The progressive vision loss associated with Stargardt is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula. Stargardt disease is currently affecting about 30,000 people in the United States.2
"This open IND for ACDN-01 by the FDA—the first regulator to have cleared ACDN-01 for clinical development—represents an important milestone for Ascidian and the broader field of RNA editing," said Michael Ehlers, MD, PhD, president and interim CEO of Ascidian Therapeutics, in the press release. "We chose to go to the FDA first because we have conviction in the rigor of our data, and that by editing RNA and not DNA, the Ascidian approach brings unique advantages with potential to transform the lives of people living with Stargardt disease and, more broadly, to dramatically expand the reach of genetic medicine."
Ascidian expects to initiate enrollment in the Phase I/II STELLAR study of ACDN-01 in Stargardt disease in the first half of 2024. The open-label study will evaluate the safety and efficacy of a single dose of ACDN-01 via subretinal injection. In addition to patients with Stargardt, the therapeutic will also be evaluated in individuals with other ABCA4 retinopathies.
"The advancement of Ascidian's first-of-its-kind RNA exon editor from the lab to the clinic is a unique and novel therapeutic approach targeting the genetic cause of Stargardt disease," said Byron L. Lam, MD, director of the Mark J. Daily Inherited Retinal Disease Research Center at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, in the press release. "This is a critical step toward overcoming the challenges of Stargardt disease, such as the size of the ABCA4 gene and large number of mutations within the patient population, that have long kept Stargardt out of reach for conventional gene therapies. Stargardt patients deserve treatment options, and I am looking forward to the clinical evaluation of this promising approach."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.